Fas Ligand is a 40kDa type II membrane protein, which also known as FasL and CD95L, belongs to the tumor necrosis factor (TNF) family. In the new TNF superfamily nomenclature, FasL is referred as TNFSF6. It consists of TNFα, α and β chains of lymphotoxin (LT), CD40 ligand, and CD30 ligand. It also has four potential N-glycosylation sites which appear to be variably used.
purified recombinant mouse Fas Ligand, amino acids 132-279, expressed in NSO cells.
The monoclonal Anti-Fas Ligand antibody is suitable for western blot analysis of rat thymus homogenates to detect the recombinant rFasL molecule. The antibody is also suitable for immunoblotting at a concentration of 1-2μg/ml and ELISA at a concentration of 0.5-1.0μg/ml.
FasL is predominantly expressed on activated T cells and NK cells, whereas Fas is expressed on various cell types. The gene expression is induced by the activation of mature T cells with phorbol myristic acetate (PMA) and ionomycin, concanavalin A (Con A) or anti-CD3. After cleaving of FasL, it can generate the soluble Fas ligand, a non-covalently linked homotrimer. Membrane-bound FasL and TNFα are primary activators of their receptors. Soluble FasL may inhibit the killing effect of membrane FasL. It plays an important role in modulating immune response by inducing cell apoptosis to maintain homeostasis, self-tolerance of lymphocytes, and immune privilege. It has chemoattractant characteristics for neutrophils which indicate proinflammatory function.
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.